Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 5, 2005, Pages 279-283

  Scholl, Sebastian ^a   Loncarevic, Ivan F ^a   Krause, Claudia ^a   Clement, Joachim H ^a   Höffken, Klaus ^a   Sayer, Herbert G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Acute myeloid leukaemia; Allogeneic PBSCT; Flt3 mutation; MRD

Indexed keywords

PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CASE REPORT; CONTROLLED STUDY; DISEASE CARRIER; DISEASE COURSE; GENE MUTATION; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 17644366455     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0660-x     Document Type: Article

References (10)

1. Abu-Duhier FM, Goodeve AC, Wilson GA, et al (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113:983-988
2. Jaeger U, Kainz B (2003) Monitoring of minimal residual disease in AML: the right time for real time. Ann Hematol 82:139-147
3. Kottaridis PD, Gale RE, Frew ME, et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759
4. Nakao M, Yokota S, Iwai T, et al (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911-1918
5. Schnittger S, Schoch C, Kern W, et al (2004) Flt3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematolo 112:68-78
6. Shih LJ, Huang CF, Wu JH, et al (2004) Heterogeneous patterns of Flt3 Asp835 mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clin Cancer Res 10:1326-1332
7. Slavin S, Nagler A, Naparstek E, et al (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 3:756-763
8. Thiede C, Steudel C, Mohr B, et al (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335
9. Yamamoto Y, Kiyoi H, Nakano Y, et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434-2439
10. Stirewalt, DL, Willman CL, Radich JP (2001) Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leuk Res 25:1085-1088